List of Excipients in Branded Drug DAPZURA RT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	DAPZURA RT	daptomycin	60977-145	HYDROCHLORIC ACID
Baxter Healthcare Corporation	DAPZURA RT	daptomycin	60977-145	MANNITOL
Baxter Healthcare Corporation	DAPZURA RT	daptomycin	60977-145	SODIUM HYDROXIDE
Baxter Healthcare Corporation	DAPZURA RT	daptomycin	60977-145	SORBITOL

DAPZURA RT Excipient Strategy and Commercial Opportunities for Aztreonam Injection

Last updated: August 7, 2026

DAPZURA RT is Lupin’s injectable aztreonam product, a generic monobactam supplied as a sterile powder for reconstitution. Its principal excipient is L-arginine, which supports solubility and pH control. The commercial opportunity is concentrated in hospital supply reliability, beta-lactam-allergy treatment, antimicrobial-stewardship protocols, and differentiated presentation formats rather than in new composition-of-matter exclusivity.

What is DAPZURA RT and which excipients does it contain?

DAPZURA RT is aztreonam for injection, USP. It is supplied in single-dose vials containing aztreonam equivalent to 1 gram or 2 grams. The formulation contains L-arginine as the principal inactive ingredient and does not rely on a conventional preservative system. Reconstitution is performed with an approved diluent such as Sterile Water for Injection, 0.9% Sodium Chloride Injection, or 5% Dextrose Injection, depending on the intended route and administration conditions.[1]

Product attribute	DAPZURA RT
Active ingredient	Aztreonam
Drug class	Monobactam antibacterial
Dosage form	Sterile powder for injection
Commercial strengths	1 g and 2 g vials
Principal excipient	L-arginine
Preservative	Not identified in the public product labeling
Administration	Intravenous or intramuscular after reconstitution
Reference product	AZACTAM
FDA pathway	Abbreviated New Drug Application
Primary market	Hospital and institutional antibacterial use

The formulation is designed for parenteral administration against susceptible aerobic Gram-negative bacteria. Aztreonam has limited cross-reactivity with most beta-lactam antibiotics, although patients with prior ceftazidime hypersensitivity require particular clinical attention because of structural side-chain similarity.[1]

Why is L-arginine used in DAPZURA RT?

L-arginine is used to improve aztreonam solubility and establish a suitable formulation environment. Aztreonam is a zwitterionic molecule with limited practical solubility characteristics for a concentrated injectable product. An arginine-containing formulation permits presentation as a stable sterile powder that can be reconstituted before administration.

The excipient strategy provides four technical advantages:

1. It supports high drug loading in a small vial.
2. It permits rapid reconstitution for hospital use.
3. It avoids a complex multi-excipient parenteral system.
4. It aligns with the established formulation architecture of the reference product.

Public labeling identifies approximately 0.78 gram of L-arginine per gram of aztreonam and approximately 1.56 grams per 2-gram vial.[1] The arginine quantity is commercially relevant because it affects osmolality, electrolyte exposure, compatibility assessment, and the information required for hospital pharmacy protocols.

What formulation risks are created by arginine?

Arginine is a functional excipient, but its concentration creates several development and commercialization constraints:

• Reconstitution pH must remain within the labeled range.
• The product must maintain chemical stability after reconstitution.
• Container closure materials must not cause adsorption or extractables concerns.
• Dilution into common infusion fluids must preserve clarity and potency.
• The formulation must remain compatible with standard hospital transfer devices.
• Excessive arginine exposure may matter in patients receiving repeated or high-dose therapy, particularly those with significant metabolic or renal abnormalities.

These factors limit the value of replacing arginine with an alternative solubilizer unless the resulting product creates a clear clinical or operational advantage. For an ANDA product, a materially different excipient system can also increase formulation-development, bioequivalence, quality, and regulatory risk.

What excipient strategies are available for DAPZURA RT competitors?

The strongest opportunities are incremental presentations that improve administration, storage, or pharmacy workflow without changing the core active ingredient.

Ready-to-use or premixed aztreonam

A ready-to-use solution or pharmacy-ready premix could reduce reconstitution steps and preparation errors. The main technical barriers are chemical stability, microbial control, container compatibility, and shelf life.

Potential commercial formats include:

• Flexible infusion bags containing a standard dose.
• Pharmacy bulk packages for controlled compounding.
• Dual-chamber systems separating aztreonam from the diluent until use.
• Ready-to-administer syringes for emergency or procedural settings.

A premixed product would compete on labor savings and medication-use safety. It would also face higher manufacturing and distribution costs than a conventional lyophilized or sterile-powder vial.

Improved reconstitution system

A proprietary transfer device, vial adapter, or integrated diluent system could create operational differentiation without altering the drug formulation. Value drivers include:

• Shorter reconstitution time.
• Lower risk of needle-stick injury.
• Reduced particulate contamination.
• Easier preparation in emergency departments and intensive-care units.
• Better compatibility with automated compounding systems.

These improvements may be protectable through device or combination-product claims, although they would not necessarily create broad protection over aztreonam itself.

Low-volume concentrated presentation

A higher-concentration formulation could reduce infusion volume for patients subject to fluid restrictions. The opportunity depends on achieving acceptable osmolality, tolerability, stability, and reconstitution performance. A concentrated product may be valuable in intensive-care and pediatric settings, but it would require careful labeling and compatibility work.

Extended-stability formulation

A formulation with longer post-reconstitution stability could reduce pharmacy waste. The commercial target is not merely a longer unopened-vial shelf life. The more valuable attributes are:

• Longer room-temperature stability after reconstitution.
• Greater stability in common infusion solutions.
• Compatibility with automated dose preparation.
• Reduced need for refrigerated storage.
• Clearer beyond-use instructions for hospital pharmacies.

Any stability advantage would need to be demonstrated through comparative quality data and incorporated into the approved labeling.

Alternative container closure systems

A low-extractables vial, polymer container, or ready-to-use bag could address supply-chain and handling issues. Container innovation is most commercially useful when it reduces breakage, improves cold-chain performance, or supports automated dispensing.

What patents protect DAPZURA RT and aztreonam injection?

DAPZURA RT is a generic aztreonam injection product. The core aztreonam composition-of-matter and original AZACTAM product protections are expired. Public FDA materials identify AZACTAM as the reference listed drug for generic aztreonam injection products.[2]

IP category	Status and commercial effect
Aztreonam active-ingredient patents	Expired
Original injectable formulation rights	Expired or no longer a practical barrier to generic entry
DAPZURA RT product-specific patent estate	No broad composition-of-matter estate identified in public FDA product materials
Excipient patent risk	Possible for new arginine systems, stabilizers, premixes, or delivery devices
Device patent risk	Possible for proprietary reconstitution or administration systems
Method-of-use patents	Limited relevance where the claims cover established aztreonam antibacterial uses
Manufacturing patents	Potential relevance for sterile processing, particle control, drying, or packaging methods

The principal freedom-to-operate risk for a new entrant is unlikely to be the aztreonam molecule. It is more likely to arise from a separately protected formulation, container, transfer device, premix technology, or manufacturing process.

When does DAPZURA RT lose exclusivity?

DAPZURA RT entered through the generic pathway rather than through a new molecular entity approval. Its commercial protection therefore depends primarily on generic competition, ANDA timing, supply contracts, manufacturing scale, and any product-specific regulatory exclusivity.

The reference product’s market exclusivity has expired. No current new chemical entity exclusivity period protects DAPZURA RT. A generic competitor would generally pursue an ANDA referencing AZACTAM and demonstrate pharmaceutical equivalence, bioequivalence where applicable, and conformity with current quality requirements.[2,3]

Are there Paragraph IV challenges to DAPZURA RT?

Paragraph IV litigation is not ordinarily directed against a generic product after approval unless the generic applicant challenges an unexpired patent listed for the reference product. Because the principal AZACTAM protections are historical and the drug is an established generic injectable, the immediate Paragraph IV risk for DAPZURA RT appears limited.

Future Paragraph IV activity could arise if a sponsor obtains FDA-listed patents covering:

• A new ready-to-use aztreonam formulation.
• A premixed infusion presentation.
• A proprietary container or transfer device.
• A new method of administration.
• A specific combination with another antibacterial agent.

Such patents would protect the improvement, not the underlying aztreonam molecule.

What is the Orange Book status of DAPZURA RT?

DAPZURA RT is associated with the generic aztreonam injection market, while AZACTAM is the reference listed drug. Generic ANDA products are not generally treated as separate new-drug products with their own independent Orange Book patent estate. The relevant regulatory and patent analysis therefore centers on the reference product, its listed patents, and the ANDA certification made by each applicant.[2]

The practical Orange Book conclusions are:

• AZACTAM is the reference product for aztreonam injection.
• DAPZURA RT is a generic injectable presentation.
• No active molecule-level Orange Book barrier is apparent from the established product history.
• Any future exclusivity would more likely arise from a new formulation, device, or method-of-use product.

Does DAPZURA RT face biosimilar risk?

No. DAPZURA RT is a small-molecule injectable antibiotic, not a biologic. Biosimilar pathways do not apply. Competitive entry would occur through generic drug applications, supplemental applications, or potentially 505(b)(2) applications for materially differentiated formulations.

A new aztreonam premix with substantial formulation or delivery differences could be positioned through a 505(b)(2) strategy if the sponsor cannot rely fully on the existing generic pathway. That approach could support formulation-specific labeling, but it would increase development cost and potentially create a separate patent and exclusivity profile.

What commercial opportunities exist for DAPZURA RT excipients?

Hospital procurement and shortage mitigation

Injectable antibiotics are purchased through group purchasing organizations, hospital systems, government contracts, and distributor channels. A reliable supply of aztreonam can have value when hospitals face shortages of other Gram-negative agents or need an alternative for patients with beta-lactam allergies.

Excipient suppliers can pursue:

• Pharmaceutical-grade L-arginine supply agreements.
• Dual-source qualification programs.
• Regional inventory and emergency replenishment.
• Custom grades with controlled endotoxin, bioburden, and particle specifications.
• Technical support for formulation and sterile manufacturing.

Supply reliability may have greater purchasing value than a small raw-material price reduction because hospital substitutions can create operational disruption.

Premium administration systems

A manufacturer could command a premium for a presentation that reduces pharmacist preparation time or administration errors. The strongest targets are high-throughput hospital pharmacies, emergency departments, and facilities with centralized automated compounding.

A differentiated product would need measurable economic benefits, such as:

• Reduced preparation labor.
• Lower waste from failed reconstitution.
• Fewer ancillary supplies.
• Improved inventory management.
• Lower exposure risk for pharmacy staff.

Pediatric and fluid-restricted use

A lower-volume, higher-concentration presentation could address specialized demand. The commercial opportunity is narrower than the standard 1-gram and 2-gram vial market, but the product could receive stronger formulary consideration if it improves dosing flexibility or reduces fluid burden.

Contract manufacturing and private-label supply

Aztreonam injection can support regional and private-label strategies where the sponsor has sterile injectable capacity but lacks a broad antibacterial portfolio. Excipient and packaging suppliers can participate through integrated development packages covering formulation, filling, vialing, labeling, and regulatory documentation.

How does DAPZURA RT compare with alternative Gram-negative antibiotics?

Aztreonam has a narrower antibacterial spectrum than carbapenems and does not provide Gram-positive or anaerobic coverage. Its main clinical differentiation is activity against susceptible aerobic Gram-negative organisms and utility in selected patients with beta-lactam allergy concerns.[1]

Product category	Main advantage	Excipient or presentation opportunity
Aztreonam injection	Monobactam option for selected Gram-negative infections	Reconstitution, premix, stability, vial design
Cefepime injection	Broad hospital use and established procurement	Ready-to-use bags and stability extensions
Ceftazidime injection	Antipseudomonal activity	Premix and automated-compounding formats
Carbapenem injection	Broad-spectrum coverage	Stability, vial size, and infusion convenience
Inhaled aztreonam lysine	Local pulmonary delivery	Nebulizer compatibility and inhalation formulation

Aztreonam injection should not be confused with inhaled aztreonam lysine products such as CAYSTON. The two products have different routes of administration, excipient systems, clinical uses, and regulatory considerations.[4]

What manufacturing and IP barriers affect new DAPZURA RT competitors?

The main barriers are executional rather than molecule-level patent barriers.

Sterile powder manufacturing

A competitor must control:

• Sterility assurance.
• Endotoxin levels.
• Fill weight and content uniformity.
• Reconstitution time.
• Particulate matter.
• Container closure integrity.
• Aztreonam degradation products.
• Arginine quality and variability.

Manufacturers with established sterile injectable operations have a cost and timing advantage.

Supply-chain qualification

L-arginine is widely available, but injectable-grade qualification is more demanding than ordinary pharmaceutical or nutraceutical supply. A sponsor must establish suitable controls for identity, purity, endotoxin, bioburden, heavy metals, residual solvents, and lot-to-lot consistency.

Drug shortage and procurement risk

The commercial performance of DAPZURA RT will depend on more than nominal market share. Hospital buyers assess back-order history, fill rates, vial availability, distributor inventory, and contract reliability. A competitor with a technically similar product can win share through dependable supply and favorable contracting.

What litigation or settlement agreements affect DAPZURA RT?

No major active patent litigation or settlement barrier is identified as a central constraint on the established aztreonam injection market. The relevant litigation risk would arise from future improvement patents, particularly where a competitor launches a premix, device-enabled presentation, or new administration method.

Potential disputes could involve:

• Patent infringement claims against a new formulation.
• ANDA certification disputes involving improvement patents.
• Trade dress or trademark claims involving vial presentation.
• Contract disputes over hospital or distributor supply.
• Manufacturing ownership disputes involving process improvements.

Settlement agreements are more likely to affect a newly patented formulation than a conventional aztreonam powder-for-injection product.

How strong is the DAPZURA RT patent estate?

The patent estate is weak for the underlying drug and potentially moderate for future product improvements.

Protection layer	Relative strength
Aztreonam molecule	Low, expired
Conventional arginine-containing injectable formulation	Low to moderate, depending on claim scope and prior art
New stabilizer or concentration system	Moderate if supported by unexpected stability or manufacturing results
Ready-to-use premix	Moderate to strong if stability and container claims are difficult to design around
Reconstitution device	Moderate, subject to competing device designs
Manufacturing process	Moderate where process controls produce measurable quality advantages
Hospital-use method claims	Usually limited commercial leverage without differentiated clinical evidence

The strongest defensible strategy is a layered portfolio covering formulation composition, container system, reconstitution device, and manufacturing process. A single broad excipient claim would face substantial prior-art and enablement pressure.

Key Takeaways

• DAPZURA RT is an injectable aztreonam generic using L-arginine as its principal excipient.
• The core aztreonam molecule and original AZACTAM protections are expired.
• No biosimilar pathway applies; competition occurs through generic and differentiated injectable products.
• The most valuable excipient opportunities involve premixes, extended post-reconstitution stability, low-volume concentrations, and pharmacy-ready delivery systems.
• L-arginine supply quality, sterile manufacturing, reconstitution performance, and container compatibility are central technical issues.
• Future patent value is more likely to reside in formulation, device, packaging, and manufacturing claims than in aztreonam composition claims.
• Commercial success will depend heavily on hospital contracting, shortage mitigation, supply reliability, and pharmacy workflow economics.

FAQs

Can L-arginine in DAPZURA RT be replaced with another excipient?

A substitute solubilizer could be developed, but it would require comparative quality, stability, reconstitution, safety, and regulatory support. Replacing L-arginine would create greater regulatory and formulation risk than maintaining the established excipient system.

Is DAPZURA RT the same as inhaled aztreonam lysine?

No. DAPZURA RT is an injectable aztreonam product. Inhaled aztreonam lysine is a separate formulation designed for nebulized pulmonary delivery and has different excipients, labeling, and commercial positioning.

Can an excipient supplier patent a DAPZURA RT formulation?

An excipient supplier may obtain patents on a novel composition, concentration range, stabilizer combination, container system, or manufacturing method. Patent strength will depend on novelty, nonobviousness, enablement, and the ability to demonstrate a measurable technical advantage.

Would a ready-to-use aztreonam bag receive new regulatory exclusivity?

A differentiated ready-to-use product could potentially receive product-specific protection or exclusivity depending on its regulatory pathway and approved claims. The underlying aztreonam molecule would remain off patent.

What is the highest-value commercial improvement for aztreonam injection?

A pharmacy-ready presentation with extended stability and reduced preparation requirements has the clearest commercial rationale. It could reduce labor, waste, and administration complexity in institutional settings.

References

1. U.S. Food and Drug Administration. (2024). DAPZURA RT (aztreonam for injection, USP) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). ANDA approvals and generic drug development guidance.
4. U.S. Food and Drug Administration. (2024). CAYSTON (aztreonam for inhalation solution) prescribing information.